Display options
Cite
Gálvez-Prieto B, Somoza B, Gil-Ortega M, et al. Anticontractile Effect of Perivascular Adipose Tissue and Leptin are Reduced in Hypertension. Front Pharmacol. 2012;3:103doi: 10.3389/fphar.2012.00103.
Gálvez-Prieto, B., Somoza, B., Gil-Ortega, M., García-Prieto, C. F., de Las Heras, A. I., González, M. C., Arribas, S., Aranguez, I., Bolbrinker, J., Kreutz, R., Ruiz-Gayo, M., & Fernández-Alfonso, M. S. (2012). Anticontractile Effect of Perivascular Adipose Tissue and Leptin are Reduced in Hypertension. Frontiers in pharmacology, 3103. https://doi.org/10.3389/fphar.2012.00103
Gálvez-Prieto, Beatriz, et al. "Anticontractile Effect of Perivascular Adipose Tissue and Leptin are Reduced in Hypertension." Frontiers in pharmacology vol. 3 (2012): 103. doi: https://doi.org/10.3389/fphar.2012.00103
Gálvez-Prieto B, Somoza B, Gil-Ortega M, García-Prieto CF, de Las Heras AI, González MC, Arribas S, Aranguez I, Bolbrinker J, Kreutz R, Ruiz-Gayo M, Fernández-Alfonso MS. Anticontractile Effect of Perivascular Adipose Tissue and Leptin are Reduced in Hypertension. Front Pharmacol. 2012 Jun 05;3:103. doi: 10.3389/fphar.2012.00103. eCollection 2012. PMID: 22679436; PMCID: PMC3367267.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2012 Jun 05;3:103. doi: 10.3389/fphar.2012.00103. eCollection 2012.

Anticontractile Effect of Perivascular Adipose Tissue and Leptin are Reduced in Hypertension.

Frontiers in pharmacology

Beatriz Gálvez-Prieto, Beatriz Somoza, Marta Gil-Ortega, Concha F García-Prieto, Ana I de Las Heras, M Carmen González, Silvia Arribas, Isabel Aranguez, Juliane Bolbrinker, Reinhold Kreutz, Mariano Ruiz-Gayo, Maria S Fernández-Alfonso

Affiliations

  1. Instituto Pluridisciplinar, Facultad de Farmacia, Universidad Complutense de Madrid Madrid, Spain.

PMID: 22679436 PMCID: PMC3367267 DOI: 10.3389/fphar.2012.00103

Abstract

Leptin causes vasodilatation both by endothelium-dependent and -independent mechanisms. Leptin is synthesized by perivascular adipose tissue (PVAT). The hypothesis of this study is that a decrease of leptin production in PVAT of spontaneously hypertensive rats (SHR) might contribute to a diminished paracrine anticontractile effect of the hormone. We have determined in aorta from Wistar-Kyoto (WKY) and SHR (i) leptin mRNA and protein levels in PVAT, (ii) the effect of leptin and PVAT on contractile responses, and (iii) leptin-induced relaxation and nitric oxide (NO) production. Leptin mRNA and protein expression were significantly lower in PVAT from SHR. Concentration-response curves to angiotensin II were significantly blunted in presence of PVAT as well as by exogenous leptin (10(-9) M) only in WKY. This anticontractile effect was endothelium-dependent. Vasodilatation induced by leptin was smaller in SHR than in WKY, and was also endothelium-dependent. Moreover, release of endothelial NO in response to acute leptin was higher in WKY compared to SHR, but completely abolished in the absence of endothelium. In conclusion, the reduced anticontractile effect of PVAT in SHR might be attributed to a reduced PVAT-derived leptin and to an abrogated effect of leptin on endothelial NO release probably due to an impaired activation of endothelial NO synthase.

Keywords: angiotensin II; hypertension; leptin; nitric oxide; perivascular adipose tissue

References

  1. Interact Cardiovasc Thorac Surg. 2011 Feb;12(2):170-3 - PubMed
  2. J Endocrinol. 2008 Apr;197(1):55-64 - PubMed
  3. Physiol Rev. 2004 Jan;84(1):277-359 - PubMed
  4. Endocrinology. 1998 Sep;139(9):3681-90 - PubMed
  5. Nature. 1994 Dec 1;372(6505):425-32 - PubMed
  6. Curr Hypertens Rep. 2008 Dec;10(6):434-9 - PubMed
  7. Diabetes. 2002 Jan;51(1):168-73 - PubMed
  8. Hypertension. 2002 Feb;39(2 Pt 2):656-61 - PubMed
  9. Mediators Inflamm. 2010;2010:105489 - PubMed
  10. Hypertension. 1986 Apr;8(4):344-8 - PubMed
  11. Eur Heart J. 2006 Oct;27(19):2294-9 - PubMed
  12. Cardiovasc Res. 2006 Jul 15;71(2):363-73 - PubMed
  13. Endocrinology. 2002 Sep;143(9):3555-60 - PubMed
  14. Neuron. 1998 Dec;21(6):1375-85 - PubMed
  15. Cardiovasc Res. 2007 Sep 1;75(4):719-27 - PubMed
  16. Arterioscler Thromb Vasc Biol. 2006 Jun;26(6):1297-302 - PubMed
  17. FASEB J. 2001 Jun;15(8):1357-66 - PubMed
  18. Hypertension. 2004 Sep;44(3):271-6 - PubMed
  19. J Physiol. 2007 Oct 1;584(Pt 1):5-9 - PubMed
  20. Nat Med. 1996 May;2(5):589-93 - PubMed
  21. FASEB J. 2002 Jul;16(9):1057-63 - PubMed
  22. Braz J Med Biol Res. 2000 Jun;33(6):605-18 - PubMed
  23. Hypertension. 2002 Jan;39(1):69-74 - PubMed
  24. Br J Pharmacol. 2007 Jun;151(3):323-31 - PubMed
  25. Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1711-7 - PubMed
  26. Br J Pharmacol. 2003 Oct;140(4):647-52 - PubMed
  27. Curr Pharm Des. 2007;13(21):2185-92 - PubMed
  28. Eur J Pharmacol. 2011 Apr 10;656(1-3):68-73 - PubMed
  29. Clin Sci Mol Med Suppl. 1975 Jun;2:225s-238s - PubMed
  30. Br J Pharmacol. 2012 Feb;165(3):633-42 - PubMed
  31. J Hypertens. 2009 Apr;27(4):782-90 - PubMed
  32. Trends Pharmacol Sci. 2004 Dec;25(12):647-53 - PubMed
  33. Diabetes. 2000 Feb;49(2):293-7 - PubMed
  34. Diabetes. 1999 Apr;48(4):903-8 - PubMed
  35. Cardiovasc Res. 2005 Feb 1;65(2):478-86 - PubMed
  36. Methods Find Exp Clin Pharmacol. 2009 Jun;31(5):325-9 - PubMed
  37. Kidney Int. 2002 Jul;62(1):181-91 - PubMed
  38. Mol Cell Biochem. 2006 Feb;283(1-2):153-7 - PubMed
  39. Clin Exp Hypertens. 2009 Jun;31(4):355-63 - PubMed
  40. Endocrinology. 2007 Jan;148(1):324-31 - PubMed
  41. Am J Physiol Heart Circ Physiol. 2004 Mar;286(3):H1107-13 - PubMed
  42. Endocrinology. 2010 Jul;151(7):3299-306 - PubMed
  43. Biochem Biophys Res Commun. 2000 Jul 5;273(2):745-9 - PubMed
  44. Obes Res. 2005 Apr;13(4):687-92 - PubMed
  45. Endocrinology. 2007 Mar;148(3):924-31 - PubMed

Publication Types